BNGO - Aquestive Therapeutics: Remains On The Track After Q2 Results
Overview
Aquestive Therapeutics (NASDAQ:AQST) has posted Q2 results beating the street by $0.36 in EPS and $12.91 million in revenues, on the back of a sturdy quarter related to sales of its licensed commercialised pharmaceutical products, including Sympazan, Suboxone, Kynmobi and Zuplenz. Sympazan is an oral film of which the active ingredient is used in the management of seizures; whilst Zuplenz is the marketed brand for the compound Ondansetron and is the gold standard in anti-nausea medication, whilst Suboxone is an opioid-based drug for pain-relief. The company has exclusivity over these compounds and